Research In Brief
This article was originally published in The Gray Sheet
Executive Summary
St. Jude launches first U.S. trial of its renal denervation system. Universal decolonization reduces ICU infections better than screening-based approaches. More research news.
You may also be interested in...
St. Jude Halts U.S. Renal Denervation Trial, Citing Slow Patient Enrollment
Patient-recruitment challenges have led St. Jude to halt a U.S. clinical trial of its EnligHTN renal denervation system. The company says it is working with FDA to design a new trial.
New Products: St. Jude Renal Denervation; Zimmer Shoulder; Respicardia Sleep Apnea Pulse Generator
St. Jude’s next-generation EnligHTN renal denervation system earns a CE mark. Respicardia launches First implant pulse generator to treat central sleep apnea. FDA clears Zimmer shoulder system. GeneDX launches BRCA1 and BRCA2 genetic tests not long after Supreme Court overturns Myriad’s monopoly on the tests.
EuroPCR in Brief
New clinical data from St. Jude Medical’s and Boston Scientific’s trials of renal denervation devices to treat hypertension show progress in the development of these novel blood pressure therapies, but both companies remain behind Medtronic. More news from EuroPCR, the official congress of the European Association of Percutaneous Cardiovascular Interventions.